ITPR2 and fatty liver disease: In addition, a recent study showed that the hepatokine orosomucoid (ORM) 2 binds to IP3R2, leading to the activation of AMPK signalling and suppression of SREBP-mediated lipogenic gene expression in the liver, with ORM2 protein therapy improving hepatic steatosis and MASH in mice [555].